Cargando…

Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020–2022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality

BACKGROUND: The o severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic has killed millions of people and caused widespread concern around the world. Multiple genetic variants of SARS-CoV-2 have been identified as the pandemic continues. Concerns have been raised about high transmissibility a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kandeel, Amr, Moatasim, Yassmin, Fahim, Manal, Bahaaeldin, Hala, El-Shesheny, Rabeh, Roshdy, Wael H., Kamel, Mina N., Shawky, Shaymaa, Gomaa, Mokhtar, Naguib, Amel, Guindy, Nancy El, Deghedy, Ola, Kamel, Reham, Khalifa, Mohamed, Galal, Ramy, Hassany, Mohamed, Mahmoud, Galal, Kandeil, Ahmed, Afifi, Salma, Mohsen, Amira, Fattah, Mohammad Abdel, Kayali, Ghazi, Ali, Mohamed A., Abdelghaffar, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439637/
https://www.ncbi.nlm.nih.gov/pubmed/37596534
http://dx.doi.org/10.1186/s12879-023-08527-y
_version_ 1785092993571618816
author Kandeel, Amr
Moatasim, Yassmin
Fahim, Manal
Bahaaeldin, Hala
El-Shesheny, Rabeh
Roshdy, Wael H.
Kamel, Mina N.
Shawky, Shaymaa
Gomaa, Mokhtar
Naguib, Amel
Guindy, Nancy El
Deghedy, Ola
Kamel, Reham
Khalifa, Mohamed
Galal, Ramy
Hassany, Mohamed
Mahmoud, Galal
Kandeil, Ahmed
Afifi, Salma
Mohsen, Amira
Fattah, Mohammad Abdel
Kayali, Ghazi
Ali, Mohamed A.
Abdelghaffar, Khaled
author_facet Kandeel, Amr
Moatasim, Yassmin
Fahim, Manal
Bahaaeldin, Hala
El-Shesheny, Rabeh
Roshdy, Wael H.
Kamel, Mina N.
Shawky, Shaymaa
Gomaa, Mokhtar
Naguib, Amel
Guindy, Nancy El
Deghedy, Ola
Kamel, Reham
Khalifa, Mohamed
Galal, Ramy
Hassany, Mohamed
Mahmoud, Galal
Kandeil, Ahmed
Afifi, Salma
Mohsen, Amira
Fattah, Mohammad Abdel
Kayali, Ghazi
Ali, Mohamed A.
Abdelghaffar, Khaled
author_sort Kandeel, Amr
collection PubMed
description BACKGROUND: The o severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic has killed millions of people and caused widespread concern around the world. Multiple genetic variants of SARS-CoV-2 have been identified as the pandemic continues. Concerns have been raised about high transmissibility and lower vaccine efficacy against omicron. There is an urgent need to better describe how omicron will impact clinical presentation and vaccine efficacy. This study aims at comparing the epidemiologic, clinical, and genomic characteristics of the omicron variant prevalent during the fifth wave with those of other VOCs between May 2020 and April 2022. METHODS: Epidemiological data were obtained from the National Electronic Diseases Surveillance System. Secondary data analysis was performed on all confirmed COVID-19 patients. Descriptive data analysis was performed for demographics and patient outcome and the incidence of COVID-19 was calculated as the proportion of SARS-CoV-2 confirmed patients out of the total population of Egypt. Incidence and characteristics of the omicron cohort from January- April 2022, were compared to those confirmed from May 2020-December 2021. We performed the whole-genome sequencing of SARS-CoV-2 on 1590 specimens using Illumina sequencing to describe the circulation of the virus lineages in Egypt. RESULTS: A total of 502,629 patients enrolled, including 60,665 (12.1%) reported in the fifth wave. The incidence rate of omicron was significantly lower than the mean of incidences in the previous subperiod (60.1 vs. 86.3/100,000 population, p < 0.001). Symptoms were reported less often in the omicron cohort than in patients with other variants, with omicron having a lower hospitalization rate and overall case fatality rate as well. The omicron cohort tended to stay fewer days at the hospital than did those with other variants. We analyzed sequences of 2433 (1590 in this study and 843 were obtained from GISAID platform) Egyptian SARS-CoV-2 full genomes. The first wave that occurred before the emergence of global variants of concern belonged to the B.1 clade. The second and third waves were associated with C.36. Waves 4 and 5 included B.1.617.2 and BA.1 clades, respectively. CONCLUSIONS: The study indicated that Omicron-infected patients had milder symptoms and were less likely to be hospitalized; however, patients hospitalized with omicron had a more severe course and higher fatality rates than those hospitalized with other variants. Our findings demonstrate the importance of combining epidemiological data and genomic analysis to generate actionable information for public health decision-making. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-023-08527-y.
format Online
Article
Text
id pubmed-10439637
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104396372023-08-20 Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020–2022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality Kandeel, Amr Moatasim, Yassmin Fahim, Manal Bahaaeldin, Hala El-Shesheny, Rabeh Roshdy, Wael H. Kamel, Mina N. Shawky, Shaymaa Gomaa, Mokhtar Naguib, Amel Guindy, Nancy El Deghedy, Ola Kamel, Reham Khalifa, Mohamed Galal, Ramy Hassany, Mohamed Mahmoud, Galal Kandeil, Ahmed Afifi, Salma Mohsen, Amira Fattah, Mohammad Abdel Kayali, Ghazi Ali, Mohamed A. Abdelghaffar, Khaled BMC Infect Dis Research BACKGROUND: The o severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic has killed millions of people and caused widespread concern around the world. Multiple genetic variants of SARS-CoV-2 have been identified as the pandemic continues. Concerns have been raised about high transmissibility and lower vaccine efficacy against omicron. There is an urgent need to better describe how omicron will impact clinical presentation and vaccine efficacy. This study aims at comparing the epidemiologic, clinical, and genomic characteristics of the omicron variant prevalent during the fifth wave with those of other VOCs between May 2020 and April 2022. METHODS: Epidemiological data were obtained from the National Electronic Diseases Surveillance System. Secondary data analysis was performed on all confirmed COVID-19 patients. Descriptive data analysis was performed for demographics and patient outcome and the incidence of COVID-19 was calculated as the proportion of SARS-CoV-2 confirmed patients out of the total population of Egypt. Incidence and characteristics of the omicron cohort from January- April 2022, were compared to those confirmed from May 2020-December 2021. We performed the whole-genome sequencing of SARS-CoV-2 on 1590 specimens using Illumina sequencing to describe the circulation of the virus lineages in Egypt. RESULTS: A total of 502,629 patients enrolled, including 60,665 (12.1%) reported in the fifth wave. The incidence rate of omicron was significantly lower than the mean of incidences in the previous subperiod (60.1 vs. 86.3/100,000 population, p < 0.001). Symptoms were reported less often in the omicron cohort than in patients with other variants, with omicron having a lower hospitalization rate and overall case fatality rate as well. The omicron cohort tended to stay fewer days at the hospital than did those with other variants. We analyzed sequences of 2433 (1590 in this study and 843 were obtained from GISAID platform) Egyptian SARS-CoV-2 full genomes. The first wave that occurred before the emergence of global variants of concern belonged to the B.1 clade. The second and third waves were associated with C.36. Waves 4 and 5 included B.1.617.2 and BA.1 clades, respectively. CONCLUSIONS: The study indicated that Omicron-infected patients had milder symptoms and were less likely to be hospitalized; however, patients hospitalized with omicron had a more severe course and higher fatality rates than those hospitalized with other variants. Our findings demonstrate the importance of combining epidemiological data and genomic analysis to generate actionable information for public health decision-making. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-023-08527-y. BioMed Central 2023-08-18 /pmc/articles/PMC10439637/ /pubmed/37596534 http://dx.doi.org/10.1186/s12879-023-08527-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kandeel, Amr
Moatasim, Yassmin
Fahim, Manal
Bahaaeldin, Hala
El-Shesheny, Rabeh
Roshdy, Wael H.
Kamel, Mina N.
Shawky, Shaymaa
Gomaa, Mokhtar
Naguib, Amel
Guindy, Nancy El
Deghedy, Ola
Kamel, Reham
Khalifa, Mohamed
Galal, Ramy
Hassany, Mohamed
Mahmoud, Galal
Kandeil, Ahmed
Afifi, Salma
Mohsen, Amira
Fattah, Mohammad Abdel
Kayali, Ghazi
Ali, Mohamed A.
Abdelghaffar, Khaled
Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020–2022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality
title Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020–2022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality
title_full Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020–2022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality
title_fullStr Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020–2022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality
title_full_unstemmed Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020–2022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality
title_short Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020–2022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality
title_sort comparison of sars-cov-2 omicron variant with the previously identified sars-cov-2 variants in egypt, 2020–2022: insight into sars-cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439637/
https://www.ncbi.nlm.nih.gov/pubmed/37596534
http://dx.doi.org/10.1186/s12879-023-08527-y
work_keys_str_mv AT kandeelamr comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT moatasimyassmin comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT fahimmanal comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT bahaaeldinhala comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT elsheshenyrabeh comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT roshdywaelh comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT kamelminan comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT shawkyshaymaa comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT gomaamokhtar comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT naguibamel comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT guindynancyel comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT deghedyola comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT kamelreham comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT khalifamohamed comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT galalramy comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT hassanymohamed comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT mahmoudgalal comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT kandeilahmed comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT afifisalma comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT mohsenamira comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT fattahmohammadabdel comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT kayalighazi comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT alimohameda comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality
AT abdelghaffarkhaled comparisonofsarscov2omicronvariantwiththepreviouslyidentifiedsarscov2variantsinegypt20202022insightintosarscov2genomeevolutionanditsimpactonepidemiologyclinicalpicturediseaseseverityandmortality